CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05635838
NCT05635838Phase 2Completed

A Phase 2, Double-Blind, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Incyte Corporation·interventional·Posted Dec 2, 2022·Updated Nov 1, 2024

In Brief

A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle cream for Hidradenitis Suppurativa. Completed, enrolled 69 participants across 20 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants with Hidradenitis Suppurativa. This is a randomized 16-week double-blind, vehicle-controlled (DBVC) study followed by a 16 week open label extension period (OLE) with an active treatment for participants who complete the DBVC period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedDec 2, 2022
Enrollment StartDec 7, 2022
Primary CompletionOct 19, 2023
Study CompletionMar 14, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.6 years ago

Interventions

Ruxolitinib creamdrug

Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

Vehicle creamdrug

Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.